March 05, 2026 — 57 articles reviewed
This cycle’s coverage centered on reassuring longitudinal data about cannabis and cognitive aging in older adults, mounting evidence that THC blood levels are poor proxies for driving impairment, and persistent access failures for some of the most vulnerable patient populations in the U.S. and U.K. Alongside these clinical themes, significant regulatory and industry developments signaled shifting ground at the federal level and across international markets.
🧠 Cannabis, Cognitive Aging, and Dementia Risk in Older Adults
A single large Israeli cohort study of over 67,000 older adults received extensive coverage this cycle, consistently reporting no significant association between lifetime cannabis use and cognitive decline or dementia risk. This prospective finding directly challenges the long-held clinical assumption that cumulative cannabis exposure accelerates neurodegeneration, and it carries real weight for geriatric prescribers who have historically cited cognitive harm as a reason to withhold cannabis from aging patients. Separately, a UK Biobank and Million Veteran Program analysis found markers of modest accelerated brain aging in regular cannabis users, approximately 2.8 years, reminding us that the picture is not uniformly reassuring, particularly for younger or heavier-use populations. The practical takeaway is that lifetime use alone should not be treated as a contraindication in older adults, but clinicians still need to individualize based on age of onset, use intensity, fall risk, and drug interactions.
- #78Study finds no links between cannabis use and cognitive decline or dementia in older people
- #75Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORML
- #75Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …
- #75Cannabis Use and Brain Aging: What a Major Study Reveals – Born2Invest
🚗 Driving Impairment, THC Testing, and the Gap Between Detection and Function
A controlled study examining driving performance 12 to 15 hours after cannabis use found no significant impairment the following morning, with THC blood and oral fluid concentrations showing poor correlation with actual driving metrics. This finding was widely covered and reinforces what pharmacology has long suggested: cannabinoid detection is not the same as functional impairment, and policies built on presence-based testing penalize patients rather than protecting roads. Complementary coverage of cannabis breathalyzers and saliva tests highlighted their fundamental inability to distinguish past use from current intoxication, while an Australian regulatory proposal to exempt medicinal cannabis patients from automatic driving penalties signals that some jurisdictions are beginning to align law with science. Clinicians should counsel patients that individual variability still matters, but the blanket assumption that any detectable THC equals unsafe driving is not supported by the current evidence base.
- #75Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12–15 …
- #65Dabney: Weed breathalyzers and saliva tests? Let’s be real about their limits. – Star Tribune
- #65Drivers who test positive for medicinal cannabis could get behind the wheel – YouTube
- #35Ontario Labour Arbitration Decision Shows Proving Cannabis Impairment Is Key to …
🧒 Pediatric Epilepsy Access and the UK’s Ongoing Policy Failure
Multiple outlets covered a single UK campaign launched in memory of a mother whose advocacy helped change British medical cannabis law, spotlighting the persistent gap between legal authorization and actual NHS access for children with drug-resistant epilepsy. Despite the 2018 rescheduling of cannabis-based medicinal products, funding barriers, prescribing hesitancy, and absent commissioning pathways continue to leave eligible pediatric patients without treatment that has demonstrated efficacy in conditions like Dravet syndrome and Lennox-Gastaut syndrome. Families are forced into impossible choices between unaffordable private prescriptions, unregulated products, or watching their children seize without intervention. This is not a knowledge gap; it is an implementation failure, and clinicians treating refractory pediatric epilepsy should be prepared to advocate for systemic change while navigating whatever access pathways currently exist.
- #72Campaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis Law
⚖️ U.S. Regulatory Shifts: State Rollouts, Federal Tensions, and Industry Organization
Alabama is finally launching its medical cannabis program after nearly five years of regulatory delay, giving patients with qualifying conditions their first legal access to standardized products under physician supervision. Meanwhile, Oklahoma is considering rolling back one of the most permissive medical cannabis frameworks in the country after rapid expansion exposed significant regulatory gaps, a cautionary example of what happens when licensing infrastructure fails to keep pace with patient demand. At the federal level, the Department of Transportation reaffirmed that medical cannabis use provides no exemption from workplace drug testing, leaving patients in safety-sensitive jobs choosing between treatment and employment. A new cross-border industry coalition and executive actions aimed at accelerating DEA research licensing signal momentum, but whether these developments ultimately serve patients or primarily serve commercial interests remains an open question that clinicians should watch closely.
- #55Congressional Lawmakers Approve Farm Bill With Hemp Provisions—But Not The THC Ban …
- #48Pres. Trump’s Marijuana Executive Mandate Accelerates MMJ International Holdings … – Newswire
- #45The Wait is Over: Medical Cannabis set to roll out in April | WHNT.com
- #45Use Of Medical Marijuana Or Hemp Doesn’t Excuse Drug Testing Violations, Trump’s …
- #45Cannabis industry launches organization to further US policy changes with members from …
- #45Ricketts addresses Congress leaving Nebraska off list protecting state medical cannabis laws
- #42Oklahoma Seeks to Backtrack on Medical Marijuana as Pitfalls Multiply
🔬 Mental Health, GLP-1 Medications, and Emerging Therapeutic Science
A widely covered study linking rising cannabis use to poor mental health outcomes in older adults generated significant attention, but the critical clinical distinction between causation and self-medication remains unresolved in the data. Clinicians should screen older patients for both cannabis use and psychiatric symptoms concurrently, recognizing that high-THC daily use in someone with baseline psychiatric vulnerability is a fundamentally different clinical scenario than low-dose, supervised use for a specific indication. On a separate and promising front, emerging research on GLP-1 receptor agonists suggests these medications may reduce substance use disorders across multiple drug classes simultaneously by modulating reward pathways, potentially opening a novel pharmacological approach for patients with cannabis use disorder alongside metabolic disease. Meanwhile, a Northern Ireland biotech startup secured funding to develop next-generation endocannabinoid system modulators for obesity and epilepsy, representing the kind of precision pharmacology that could eventually offer patients targeted therapeutic benefit without the variability of whole-plant products.
- #75Study Links Rising Cannabis Use to Poor Mental Health – HealthDay
- #72Study Links Rising Cannabis Use to Poor Mental Health – U.S. News & World Report
- #72What to know about how GLP-1 medications might fight addiction – The Washington Post
- #65Omagh biotech start-up in funding boost for research into obesity and epilepsy
- #62GLP-1 medications get at the heart of addiction, study finds
- #45Substance use on the rise among gen Z in their early 20s | UCL News
🏥 End-of-Life Care: Washington Moves to Keep Cannabis at the Bedside
Washington State senators advanced legislation allowing terminally ill patients to continue using authorized medical cannabis during hospital stays, closing a gap that has forced dying patients to choose between inpatient care and the symptom relief they depend on. The bill requires healthcare facilities to verify patient authorization documentation and maintain records of use, creating an administrative framework that balances patient autonomy with institutional accountability. For palliative care clinicians, this means cannabis can now be integrated into comprehensive end-of-life symptom management alongside conventional medications rather than being excluded by default. The argument for keeping cannabis out of the hospital at the end of life was never medical; it was bureaucratic, and this legislation begins to correct that.
- #72Washington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In Hospitals
The through-line across this entire cycle is the distance between what the evidence supports and what systems actually allow, whether that is an older adult denied a safe medicine over unfounded dementia fears, a child seizing because funding did not follow the law, or a dying patient forced to leave the hospital to access relief. Our job as clinicians is to close that gap, one patient and one honest conversation at a time.